Yelena Y. Janjigian, MD, discusses the standard approval of pembrolizumab plus trastuzumab and chemotherapy for the treatment ...

The impact of physical and nutritional rehabilitation post bone marrow transplant in patients with hematologic malignancies ...

Panelists discuss how optimizing shared-care models between academic and community centers enhances continuity in complex hematologic malignancies. Key monitoring parameters for tagraxofusp include ...

A phase 3 trial plans to further assess neoadjuvant darovasertib for the potential treatment of patients with primary uveal ...

The fourth cohort of an ongoing phase 1/2 has dosed its first patient with TTX-MC138 in advanced solid tumors.

A panelist discusses how graft-vs-host disease (GVHD) manifests through a complex constellation of symptoms affecting ...

Carrillo, MD, evaluates the current state of the global availability of clinical trials for patients with renal cell ...

During a live event, Payal D. Shah, MD, discusses the case of a woman with metastatic breast cancer and the data for third-line sacituzumab govitecan.

Jennifer Chan, MD, MPH, discussed the findings from the phase 3 CABINET trial leading to the FDA approval of cabozantinib in patients with neuroendocrine tumors.

Experts discuss how the 5-year outcomes of polatuzumab have influenced its position in current NCCN guidelines for diffuse ...

Experts discuss the 5-year efficacy and safety outcomes of polatuzumab in diffuse large B-cell lymphoma (DLBCL), highlighting ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.